Please login to the form below

Not currently logged in
Email:
Password:

simtuzumab

This page shows the latest simtuzumab news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolsters NASH pipeline with $201m Dicerna deal

Boehringer bolsters NASH pipeline with $201m Dicerna deal

inhibitor acquired from Nimbus in a $1.2bn deal last year, after its lead inhouse drug simtuzumab failed to show efficacy in trials.

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics